EXIANT

WIPO WIPO 2019

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark EXIANT was filed as Word mark on 10/03/2019 at the World Intellectual Property Organization.

Trademark Details Last update: March 29, 2023

Trademark form Word mark
File reference 1537269
Countries Canada China European Community United Kingdom Israel Japan South Korea Mexico
Base trademark US No. 88381334, April 11, 2019
Application date October 3, 2019
Expiration date October 3, 2029

Trademark owner

157 Technology Drive
Irvine CA 92618
US

Trademark representatives

P.O. Box 1135 Chicago IL 60690 US

goods and services

05 Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; and for use in oncology; diagnostic preparations and/or reagents for clinical or medical laboratory use; pharmaceutical mineral supplements and preparations
09 Downloadable software for the facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields; downloadable software in the nature of a mobile application for facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields
10 Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors
35 Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancer, chemotherapy and pharmaceutical products in the nature of medical referrals (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); providing an online commercial information directory in the field of patient support featuring information regarding healthcare providers, sites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations
36 Providing healthcare administration, namely, providing insurance verification and prior authorization services for others (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations)
41 Educational services, namely, development and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting classes, seminars, conferences, and workshops in the field of the use of prescription pharmaceutical products for medical disorders, in the field of cancer, patient care; educational and entertainment services, namely, providing a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email, and blogs in the medical, pharmaceutical and health fields
42 Medical and pharmaceutical research services; pharmaceutical research and development
44 Patient support services relating to the treatment of medical disorders, namely, providing online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information services, namely, providing medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing a website featuring information in the medical and health fields (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); providing a website featuring information in the field of the diagnostic, prophylactic and therapeutic properties of pharmaceuticals (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); providing information in the medical field and information in the field of the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing health information; providing patients with information in the medical field; providing health information, namely, providing data on the genetics and genetic sequencing of cancer tumors and cells; genetic sequencing diagnostics and testing

Trademark history

Date Document number Area Entry
February 8, 2023 2023/13 Gaz CA RAW: Rule 18ter(2)(ii) GP following a provisional refusal
June 9, 2022 2022/25 Gaz JP RAW: No Effect Limitation
April 4, 2022 2022/15 Gaz EM RAW: No Effect Limitation
March 24, 2022 2022/13 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
February 24, 2022 2022/11 Gaz RAW: Limitation
January 14, 2022 2022/3 Gaz KR RAW: Rule 18ter(2)(ii) GP following a provisional refusal
November 19, 2021 2021/47 Gaz MX Rejection
November 2, 2021 2021/48 Gaz IL RAW: Rule 18ter(2)(ii) GP following a provisional refusal
October 21, 2021 2021/43 Gaz CA Rejection
September 3, 2021 JP Rejection
August 26, 2021 2021/35 Gaz JP Rejection
March 25, 2021 2021/12 Gaz KR Rejection
February 12, 2021 2021/7 Gaz GB RAW: Rule 18ter(2)(ii) GP following a provisional refusal
February 2, 2021 2021/8 Gaz EM RAW: Rule 18ter(2)(ii) GP following a provisional refusal
October 29, 2020 2020/45 Gaz CN Rejection
September 30, 2020 2020/41 Gaz IL Rejection
September 29, 2020 2020/42 Gaz EM Rejection
July 17, 2020 2020/30 Gaz GB Rejection
July 15, 2020 2020/31 Gaz EM Rejection
October 3, 2019 2020/24 Gaz US Registration

ID: 141537269